Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. There is strong evidence for widespread brain changes following Covid-19. Alzheimer’s disease), or by initiating a new one. depression).

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

OCTOBER 21, 2020

headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. About Replimune Replimune Group, Inc.,

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

Drug Discovery World

MAY 11, 2023

Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response. In the case of therapeutics, the aim is usually to avoid patients’ immune responses. 2015): 1727-1737. ” Biotechnology and bioengineering 112.9 Collins, Ben C.,

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2015; 15: 57-65. J Allergy Clin Immunol. 15 Fahy JV.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

MAY 13, 2021

Johnson & Johnson also announced that its Ebola vaccine regimen has received Prequalification from the WHO, which will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus.

Vaccine 52

Vaccine Virus Pharmaceutical Companies Clinical Trials 52

SugarCone Biotech

MAY 28, 2019

The immune system is tightly regulated and unkind to inappropriate signals. Jounce Therapeutics and Immune-Onc showed preclinical data at SITC 2020 on their anti-LILBR2 (ILT-4) programs, and there are additional efforts underway. Fc-hacking immune responses.

Immune Response 52

Immune Response Therapies Engineering Regulations 52

The Pharma Data

JANUARY 29, 2021

The Phase 3 ENSEMBLE trial is being conducted at the height of the COVID-19 pandemic in eight countries and three regions, at a time when disease spread has accelerated throughout the world resulting in people having increased exposure to the virus. Global Head, Janssen Research & Development. i] [link] [ii] The B.1.351 Source link.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Immune Response 40